|
1
|
World Health Organization: Cancer.
https://www.who.int/news-room/fact-sheets/detail/cancer.
Accessed September 12, 2018.
|
|
2
|
Warth A, Muley T, Herpel E, Meister M,
Herth FJ, Schirmacher P, Weichert W, Hoffmann H and Schnabel PA:
Large-scale comparative analyses of immunomarkers for diagnostic
subtyping of non-small-cell lung cancer biopsies. Histopathology.
61:1017–1025. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Noone AM, Howlader N, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al:
SEER Cancer Statistics Review, 1975-2015. National Cancer Institute
Bethesda; MD: 2018
|
|
4
|
Schneider P, Thome M, Burns K, Bodmer JL,
Hofmann K, Kataoka T, Holler N and Tschopp J: TRAIL receptors 1
(DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate
NF-kappaB. Immunity. 7:831–836. 1997. View Article : Google Scholar
|
|
5
|
Adams JM and Cory S: The Bcl-2 protein
family: Arbiters of cell survival. Science. 281:1322–1326. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Elkholi R, Renault TT, Serasinghe MN and
Chipuk JE: Putting the pieces together: How is the mitochondrial
pathway of apoptosis regulated in cancer and chemotherapy? Cancer
Metab. 2:162014. View Article : Google Scholar
|
|
7
|
Russell P, Benson JD and Denis CL:
Characterization of mutations in NOT2 indicates that it plays an
important role in maintaining the integrity of the CCR4-NOT
complex. J Mol Biol. 322:27–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zwartjes CG, Jayne S, van den Berg DL and
Timmers HT: Repression of promoter activity by CNOT2, a subunit of
the transcription regulatory Ccr4-not complex. J Biol Chem.
279:10848–10854. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jayne S, Zwartjes CG, van Schaik FM and
Timmers HT: Involvement of the SMRT/NCoR-HDAC3 complex in
transcriptional repression by the CNOT2 subunit of the human
Ccr4-Not complex. Biochem J. 398:461–467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ito K, Inoue T, Yokoyama K, Morita M,
Suzuki T and Yamamoto T: CNOT2 depletion disrupts and inhibits the
CCR4-NOT deadenylase complex and induces apoptotic cell death.
Genes Cells. 16:368–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sohn EJ, Jung DB, Lee H, Han I, Lee J, Lee
H and Kim SH: CNOT2 promotes proliferation and angiogenesis via
VEGF signaling in MDA-MB-231 breast cancer cells. Cancer Lett.
412:88–98. 2018. View Article : Google Scholar
|
|
12
|
Kim J, Yun M, Kim EO, Jung DB, Won G, Kim
B, Jung JH and Kim SH: Decursin enhances TRAIL-induced apoptosis
through oxidative stress mediated- endoplasmic reticulum stress
signalling in non-small cell lung cancers. Br J Pharmacol.
173:1033–1044. 2016. View Article : Google Scholar
|
|
13
|
Jung JH, Kwon TR, Jeong SJ, Kim EO, Sohn
EJ, Yun M and Kim SH: Apoptosis induced by tanshinone IIA and
crypto-tanshinone is mediated by distinct JAK/STAT3/5 and SHP1/2
signaling in chronic myeloid leukemia K562 cells. Evid Based
Complement Alternat Med. 2013:8056392013. View Article : Google Scholar
|
|
14
|
Jung JH, Jung DB, Kim H, Lee H, Kang SE,
Srivastava SK, Yun M and Kim SH: Zinc finger protein 746 promotes
colorectal cancer progression via c-Myc stability mediated by
glycogen synthase kinase 3β and F-box and WD repeat
domain-containing 7. Oncogene. 37:3715–3728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jeong K, Kwon HY, Jeong MS, Sohn EJ and
Kim SH: CNOT2 promotes degradation of p62/SQSTM1 as a negative
regulator in ATG5 dependent autophagy. Oncotarget. 8:46034–46046.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Faraji F, Hu Y, Yang HH, Lee MP, Winkler
GS, Hafner M and Hunter KW: Post-transcriptional control of tumor
cell autonomous metastatic potential by CCR4-NOT deadenylase CNOT7.
PLoS Genet. 12:e10058202016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee J, Jung JH, Hwang J, Park JE, Kim JH,
Park WY, Suh JY and Kim SH: CNOT2 is critically involved in
atorvastatin induced apoptotic and autophagic cell death in
non-small cell lung cancers. Cancers (Basel). 11:pii: E1470. 2019.
View Article : Google Scholar
|
|
18
|
Vicente C, Stirparo R, Demeyer S, de Bock
CE, Gielen O, Atkins M, Yan J, Halder G, Hassan BA and Cools J: The
CCR4-NOT complex is a tumor suppressor in Drosophila mela-nogaster
eye cancer models. J Hematol Oncol. 11:1082018. View Article : Google Scholar
|
|
19
|
Grivennikov SI and Karin M: Inflammatory
cytokines in cancer: Tumour necrosis factor and interleukin 6 take
the stage. Ann Rheum Dis. 70(Suppl 1): i104–i108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Vicent S, Sayles LC, Vaka D, Khatri P,
Gevaert O, Chen R, Zheng Y, Gillespie AK, Clarke N, Xu Y, et al:
Cross-species functional analysis of cancer-associated fibroblasts
identifies a critical role for CLCF1 and IL-6 in non-small cell
lung cancer in vivo. Cancer Res. 72:5744–5756. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haskins JW, Nguyen DX and Stern DF:
Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo
pathway target genes and promote cell migration. Sci Signal.
7:ra1162014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C,
Liu Z, Lin K, Xu-Monette ZY, Young KH, et al: LIF negatively
regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in
colorectal cancers. Nat Commun. 5:52182014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meares GP, Liu Y, Rajbhandari R, Qin H,
Nozell SE, Mobley JA, Corbett JA and Benveniste EN: PERK-dependent
activation of JAK1 and STAT3 contributes to endoplasmic reticulum
stress-induced inflammation. Mol Cell Biol. 34:3911–3925. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Banerjee K, Keasey MP, Razskazovskiy V,
Visavadiya NP, Jia C and Hagg T: Reduced FAK-STAT3 signaling
contributes to ER stress-induced mitochondrial dysfunction and
death in endothelial cells. Cell Signal. 36:154–162. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dickens LS, Boyd RS, Jukes-Jones R, Hughes
MA, Robinson GL, Fairall L, Schwabe JW, Cain K and Macfarlane M: A
death effector domain chain DISC model reveals a crucial role for
caspase-8 chain assembly in mediating apoptotic cell death. Mol
Cell. 47:291–305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu H, Su D, Zhang J, Ge S, Li Y, Wang F,
Gravel M, Roulston A, Song Q, Xu W, et al: Improvement of
pharmacokinetic profile of TRAIL via trimertag enhances its
antitumor activity in vivo. Sci Rep. 7:89532017. View Article : Google Scholar
|
|
27
|
Xu W, Jing L, Wang Q, Lin CC, Chen X, Diao
J, Liu Y and Sun X: Bax-PGAM5L-Drp1 complex is required for
intrinsic apoptosis execution. Oncotarget. 6:30017–30034. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Green DR and Llambi F: Cell death
signaling. Cold Spring Harb Perspect Biol. 7:2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yip KW and Reed JC: Bcl-2 family proteins
and cancer. Oncogene. 27:6398–6406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y and Zhang B: TRAIL resistance of
breast cancer cells is associated with constitutive endocytosis of
death receptors 4 and 5. Mol Cancer Res. 6:1861–1871. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Di X, Zhang G, Zhang Y, Takeda K, Rivera
Rosado LA and Zhang B: Accumulation of autophagosomes in breast
cancer cells induces TRAIL resistance through downregulation of
surface expression of death receptors 4 and 5. Oncotarget.
4:1349–1364. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fernald K and Kurokawa M: Evading
apoptosis in cancer. Trends Cell Biol. 23:620–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stupack DG: Caspase-8 as a therapeutic
target in cancer. Cancer Lett. 332:133–140. 2013. View Article : Google Scholar
|
|
35
|
Khoury MP and Bourdon JC: The isoforms of
the p53 protein. Cold Spring Harb Perspect Biol. 2:a0009272010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bourdon JC, Fernandes K, Murray-Zmijewski
F, Liu G, Diot A, Xirodimas DP, Saville MK and Lane DP: p53
isoforms can regulate p53 transcriptional activity. Genes Dev.
19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chung AH, Leisner TM, Dardis GJ, Bivins
MM, Keller AL and Parise LV: CIB1 depletion with docetaxel or TRAIL
enhances triple-negative breast cancer cell death. Cancer Cell Int.
19:262019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fagard R, Metelev V, Souissi I and
Baran-Marszak F: STAT3 inhibitors for cancer therapy: Have all
roads been explored? JAKSTAT. 2:e228822013.PubMed/NCBI
|
|
39
|
Xiong A, Yang Z, Shen Y, Zhou J and Shen
Q: Transcription factor STAT3 as a novel molecular target for
cancer prevention. Cancers (Basel). 6:926–957. 2014. View Article : Google Scholar
|
|
40
|
Santoni M, Massari F, Del Re M, Ciccarese
C, Piva F, Principato G, Montironi R, Santini D, Danesi R, Tortora
G and Cascinu S: Investigational therapies targeting signal
transducer and activator of transcription 3 for the treatment of
cancer. Expert Opin Investig Drugs. 24:809–824. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BK, et al:
Potential role of signal transducer and activator of transcription
(STAT)3 signaling pathway in inflammation, survival, proliferation
and invasion of hepatocellular carcinoma. Biochim Biophys Acta.
1835:46–60. 2013.
|
|
42
|
Tai WT, Cheng AL, Shiau CW, Huang HP,
Huang JW, Chen PJ and Chen KF: Signal transducer and activator of
transcription 3 is a major kinase-independent target of sorafenib
in hepatocellular carcinoma. J Hepatol. 55:1041–1048. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Delibrias CC, Floettmann JE, Rowe M and
Fearon DT: Downregulated expression of SHP-1 in Burkitt lymphomas
and germinal center B lymphocytes. J Exp Med. 186:1575–1583. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu C, Sun M, Liu L and Zhou GW: The
function of the protein tyrosine phosphatase SHP-1 in cancer. Gene.
306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakase K, Cheng J, Zhu Q and Marasco WA:
Mechanisms of SHP-1 P2 promoter regulation in hematopoietic cells
and its silencing in HTLV-1-transformed T cells. J Leukoc Biol.
85:165–174. 2009. View Article : Google Scholar :
|
|
46
|
Warner N, Burberry A, Franchi L, Kim YG,
McDonald C, Sartor MA and Núñez G: A genome-wide siRNA screen
reveals positive and negative regulators of the NOD2 and NF-κB
signaling pathways. Sci Signal. 6:rs32013. View Article : Google Scholar
|
|
47
|
Avalle L, Camporeale A, Morciano G,
Caroccia N, Ghetti E, Orecchia V, Viavattene D, Giorgi C, Pinton P
and Poli V: STAT3 localizes to the ER, acting as a gatekeeper for
ER-mitochondrion Ca2+ fluxes and apoptotic responses.
Cell Death Differ. 26:932–942. 2019. View Article : Google Scholar
|
